Twin Tree Management’s Neurocrine Biosciences NBIX Stock Holding History

Twin Tree Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,700	Closed	-$2.65M	–	1573
2025 Q4	$2.65M	Hold	18,700	–	–	0.02%	736
2025 Q3	$2.63M	Sell	18,700 -300	-2%	-$40.6K	0.01%	967
2025 Q2	$2.39M	Buy	19,000 +11,600	+157%	+$1.33M	﹤0.01%	1215
2025 Q1	$818K	Sell	7,400 -98,600	-93%	-$12.5M	﹤0.01%	1292
2024 Q4	$14.5M	Sell	106,000 -18,300	-15%	-$2.26M	0.03%	565
2024 Q3	$14.3M	Buy	124,300 +110,200	+782%	+$15.1M	0.03%	518
2024 Q2	$1.94M	Buy	+14,100	New	+$1.93M	﹤0.01%	970
2024 Q1	–	Sell	-24,900	Closed	-$3.28M	–	1498
2023 Q4	$3.28M	Buy	+24,900	New	+$2.87M	0.01%	969
2021 Q2	–	Sell	-35,500	Closed	-$3.45M	–	1534
2021 Q1	$3.45M	Buy	+35,500	New	+$3.72M	0.01%	728
2020 Q1	–	Sell	-16,300	Closed	-$1.75M	–	1549
2019 Q4	$1.75M	Hold	16,300	–	–	0.01%	755
2019 Q3	$1.47M	Buy	16,300 +11,300	+226%	+$1.06M	0.01%	753
2019 Q2	$422K	Hold	5,000	–	–	﹤0.01%	906
2019 Q1	$440K	Sell	5,000 -4,200	-46%	-$351K	﹤0.01%	973
2018 Q4	$657K	Buy	+9,200	New	+$881K	﹤0.01%	940

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Tree Management's NBIX Position: Q1 2026 in Review

Twin Tree Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 6,341 shares — an estimated $841K sold.

Twin Tree Management first reported a position in NBIX in Q4 2018 and held it in 22 quarters. The position peaked at $4.86M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Twin Tree Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Twin Tree Management sold 6,341 Neurocrine Biosciences shares in Q1 2026, an estimated $841K.
Twin Tree Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 22 quarters.
Twin Tree Management's Neurocrine Biosciences position peaked at $4.86M in Q4 2023.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.